Latest News
MediaTek Collaborates with NVIDIA on the RTX Spark to Power the Next Wave of Windows PC Experiences
MediaTek brings its design expertise in CPU performance and power efficiency to the groundbreaking RTX Spark, bringing local personal agents, advanced content creation, and gaming together in small, ultra-efficient Windows PCs TAIPEI, June 1, 2026 /PRNewswire/ -- MediaTek today announced its role...
2026-06-01 13:30
1408
Unitree Announces H2 Plus, an NVIDIA Isaac GR00T Reference Humanoid Robot for Academic Research
News Summary: * Unitree Robotics introduces H2 Plus, an NVIDIA Isaac GR00T Reference Humanoid Robot combining a Unitree H2 humanoid robot, Sharpa five-fingered hands for dexterous manipulation, NVIDIA Jetson Thor for advanced reasoning and control, and the new NVIDIA Isaac GR00T development pl...
2026-06-01 13:30
1388
MSI Accelerates Enterprise AI Strategy with Cloud-to-Edge Ecosystem at COMPUTEX 2026
Scaling Industrial AI from Liquid-Cooled Data Centers to Autonomous Edge Operations TAIPEI, June 1, 2026 /PRNewswire/ -- MSI, a global leader in high-performance computing and industrial solutions, returns to COMPUTEX 2026 (Booth #J0605a) to unveil its strategic AI roadmap. This year's showcase ...
2026-06-01 13:30
1323
XPENG Announces Vehicle Delivery Results for May 2026
GUANGZHOU, China, June 1, 2026 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading global AI mobility technology company, today announced its vehicle delivery results for May 2026. XPENG delivered a total of 32,158 vehicles in May, representing a 4% increas...
2026-06-01 12:47
1592
Millennium Premier Hotel New York Times Square Reopens June 1 Following Comprehensive Renovation
Millennium Hotels and Resorts unveil a reimagined boutique experience in the heart of Manhattan, celebrating the reopening with an exclusive MyMillennium member offer. NEW YORK, June 1, 2026 /PRNewswire/ -- Millennium Hotels and Resorts (MHR), an international hospitality group with over 145 hot...
2026-06-01 12:08
1766
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, todayannounced updated clinical data from its Phase I/II study evaluating ...
2026-06-01 12:00
2647
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications SEOUL, South Korea, May 31, 2026 /PRNewswire/ -- Hanmi Pharm. Co., Ltd. ("Hanmi")today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi's b...
2026-06-01 11:09
1964
ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
CHICAGO, May 31, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response rate (ORR) in patients with Late-line refractory hepatoce...
2026-06-01 10:37
2328
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product ca...
2026-06-01 08:15
1574
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved anobjective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benef...
2026-06-01 08:15
1966
ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
SUZHOU, China, May 31, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. As of the data cut-off o...
2026-06-01 08:00
1320
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
* IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR ...
2026-06-01 08:00
1165
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
* After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC * IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communication...
2026-06-01 08:00
1652
New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026
Exploring New Business Opportunities with Global Buyers TAIPEI, May 31, 2026 /PRNewswire/ -- The New Taipei City Government is leading a delegation of 20 companies specializing in smart manufacturing, automation, industrial AI, and key components to participate in AUTOMATE 2026, one of North Ame...
2026-06-01 08:00
1443
United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026
LOS ANGELES, May 31, 2026 /PRNewswire/ -- United Imaging, a global innovator in AI-powered advanced medical imaging technologies and intelligent healthcare solutions, is presenting its latest molecular imaging advancements at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annu...
2026-05-31 23:00
790
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-l...
2026-05-31 21:00
1600
Golden Goblet Competition Lineup Announced: Spotlight on the 2026 Contenders
SHANGHAI, May 30, 2026 /PRNewswire/ -- The 28th Shanghai International Film Festival (SIFF) has officially unveiled the competition selections for the 2026 Golden Goblet Awards. Held from June 12 to 21, the Festival received approximately 4,100 submissions from 125 countries and regions this ...
2026-05-31 10:33
1791
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
* Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI * In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib,...
2026-05-31 08:09
2674
The 7th China-CEEC Local Leaders' Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week Successfully Held
JINAN, China, May 30, 2026 /PRNewswire/ -- From May 25 to 29, 2026, the 7th China–CEEC Local Leaders' Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week, hosted by Shandong Provincial People's Government, the Secretariat of Cooperation between China and Centra...
2026-05-30 19:32
3691
Shaping the Future Together! What Global Guests Said at the 2026 China-CEEC Local Leaders' Meeting and Shandong Friendship Cities Week
JINAN, China, May 30, 2026 /PRNewswire/ -- From May 25 to 29, 2026, the 7th China–CEEC Local Leaders' Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week, hosted by Shandong Provincial People's Government, the Secretariat of Cooperation between China and Centra...
2026-05-30 19:28
3638
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 314 media titles]
2026-05-28 15:06The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 291 media titles]
2026-05-26 10:30
Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 289 media titles]
2026-05-28 17:34
Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 288 media titles]
2026-05-27 09:16
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 288 media titles]
2026-05-28 10:06Most Read
/DISREGARD RELEASE: Yangzhou Home Ka Crafts Co., Ltd./
2026-05-29 09:19
7106
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
2026-05-26 08:40
6149
NYSE Content Update: Mastercard Celebrates Two Decades as NYSE-Listed Company
2026-05-26 21:04
6133
